Global Cardiac Output Monitoring Device Market 2026 – 2035

The market for the cardiac output monitoring device is expected to have a CAGR of 7.9% in 2026-2035 and reach a market size of USD 1.24 billion by 2026.The cardiac output monitoring device market is projected to reach USD 1.24 billion by 2026 and USD 2.89 billion by 2035 at a CAGR of 7.9% from 2026 to 2035.

Market Highlights

• The cardiac output monitoring device market in North America was the largest, accounting for about 38% of the market in 2025.

• Asia Pacific is poised to experience the highest CAGR of 10.2% during the 2026–2035 period, mainly due to the critical care infrastructure rapidly expanding in China, where more than 80,000 new ICU beds will be added in the five-year period between 2020 and 2025.

• Minimally invasive cardiac output monitoring devices led the market with around 44% share in 2025.

• Non-invasive cardiac output monitoring devices are the fastest-growing type of product forecast to grow at a 10.8% CAGR through 2026 to 2035.

• As for technology, thermodilution-based systems accounted for the largest percentage of the technology segment at around 36% for 2025.

• In terms of end use, the hospital and ICU segment accounted for the highest share of the market with around 68% of the total market revenue in 2025.

Impact of Middle East Conflict on the Cardiac Output Monitoring Device Market

Cardiac output monitoring devices have been affected by the Middle East conflict in numerous ways, including disruption of the supply chain, realignment of healthcare budgets, and the impact on the need for trauma care in the Middle East. With the price of oil rising as a result of the region's instability, the cost of manufacturing devices and the consumables used in medical procedures has risen, albeit slightly, and this cost is being borne by both manufacturers and, to some extent, hospital procurement budgets as well.

Significant Growth Factors

Rising Global Cardiovascular Disease Burden and Critical Care Expansion Driving Baseline Monitoring Demand

According to the World Health Organization, cardiovascular disease is the primary cause of death around the world, accounting for about 17.9 million deaths each year, or about 32% of all deaths worldwide; the three major clinical events requiring cardiac output monitoring in intensive and perioperative care are ischemic heart disease, heart failure and cardiogenic shock.

As of 2025, the number of people with heart failure is estimated to be around 64 million globally, and the heart failure burden continues to rise at an estimated rate of 2.1% annually due to improved survival following acute myocardial infarction, an aging world population and an increasing prevalence of hypertension and diabetes, both risk factors for heart failure, resulting in progressive expansion of the heart failure population that requires periodic assessment and monitoring.

Cardiogenic shock, the most acute and highest acuity context for cardiac output monitoring, occurs in about 5–8% of AMI patients and has in-hospital mortality rates of ~35–45% despite current management, with the need for continuous hemodynamic monitoring to manage mechanical circulatory support devices, titrate vasopressors and inotropes, optimize fluid status, and guide the management of risk.

Since the onset of the COVID-19 pandemic, investments in the critical care bed capacity, particularly in the expansion of critical care infrastructure, have increased globally in response to the vulnerability identified by COVID-19 during the surge in demand for critical care beds, and the global critical care bed capacity in 2024 is estimated at about 1.9 million, which is an estimated 23% increase from the pre-pandemic estimate of 1.5 million.

This increase in ICU beds corresponds directly with the need for new cardiac output monitoring devices, with each new ICU bed representing a new point of device installation that is standard of care in high-acuity ICUs at major academic medical centers and large community hospitals.

Cardiac surgery ICUs see the highest number of perioperative cardiac output monitoring uses (about 1.2 million procedures per year worldwide, including CABG, valve replacement/repair, heart transplantation, and VAD implantation), and continuous cardiac output monitoring is now standard practice for 24–72 hours postoperatively in all high-volume cardiac surgery programs as a routine part of their hemodynamic management.

Goal-Directed Therapy Protocols Standardizing Cardiac Output Monitoring as a Perioperative Standard of Care

A major new impetus for the expanding use of cardiac output monitoring outside of the cardiac surgery and cardiac ICU environment — the use of evidence-based algorithms that use real-time cardiac output, stroke volume, and stroke volume variation measurements to guide fluid management and titration of vasopressors during and after major surgery to target specific cardiac endpoints — has been the progressive adoption of these protocols by clinicians.

The clinical evidence base for perioperative GDHT has significantly advanced over the last few years with multiple RCTs and meta-analyses showing that the use of COG fluid and vasopressor optimization is associated with approximately 30-40% fewer postoperative complications, such as acute kidney injury, wound infection and respiratory failure, compared with conventional perioperative hemodynamic targets for these high-risk non-cardiac surgical patients; two of the best recent studies supporting the use of GDHT in these high-risk NCS populations were the OPTIMISE II trial (UK, 734 patients) and the FEDORA trial (France, 450 patients).

What are the Major Advances Changing the Cardiac Output Monitoring Device Market Today?

Continuous Non-Invasive Cardiac Output Monitoring Technology Advancing Toward Clinical Equivalence with Invasive Reference Standards

The most significant technology development in the cardiac output monitoring device market has been the steady improvement in the accuracy, reliability, and clinical applicability of non-invasive cardiac output monitoring technologies, which historically have been limited in accuracy compared to thermodilution reference technologies and thus limited to lower acuity use, with several new platforms now showing clinical agreement to the clinically acceptable limits of agreement, as defined by Bland-Altman analysis standards, for cardiac output measuring technology validation with invasive reference technology.

Commercialized by Cheetah Medical under a system called NICOM, the bioreactance technology using the phase shift of a high frequency alternating current passing through the thorax from the electrodes placed on the skin is the most clinically validated non-invasive cardiac output monitoring technology and has been shown to be clinically acceptable in multiple independent prospective studies, notably in both ICU and postoperative patients, where there is no access to arterial or central venous lines.

Photoplethysmography (PPG)-based cardiac output monitoring is a new, non-invasive technique that requires no vascular access or skin electrode application and involves measuring characteristics of the arterial pulse waveform from peripheral pulse waveforms measured by the pulse oximeter probes, which are subsequently used to estimate stroke volume and cardiac output through proprietary algorithms, thus eliminating the requirement for any vascular access or skin electrode application and potentially allowing cardiac output monitoring to be performed from existing pulse oximeter infrastructure in any clinical setting where pulse oximeters are applied.

Current clinical use is limited to monitoring duty in lower acuity settings since there are significant errors associated with PPG cardiac output estimation in high-dose vasopressor use, significant peripheral vascular disease, and severe arrhythmias, which limit accuracy to these settings and not to replacing invasive monitoring in hemodynamically unstable patients in the ICU.

The global non-invasive cardiac output monitoring technology market is estimated to be valued at around USD 280 million in 2024 and is expected to grow at 11.4% throughout 2025 to 2035, boosted by the trajectory of the technology improvement, the growing opportunity of non-cardiac surgery GDHT adoption, and clinical preference to adopt less invasive monitoring methods where the risk of invasive device placement is higher than the benefit provided by the monitoring.

Artificial Intelligence and Machine Learning Integration Transforming Hemodynamic Data Interpretation

The use of AI and machine learning algorithms in cardiac output monitoring platforms has now turned the way intensivists and anesthesiologists use these systems from a display function to an actual clinical decision support tool, which can automatically recognize the pattern of cardiac events or predict their deterioration by analyzing a multitude of hemodynamic parameters that the human eye could not pick up.

Developed by Edwards Lifesciences and incorporated into the company's HemoSphere hemodynamic monitoring platform, the AI-powered Hypotension Prediction Index (HPI) provides anesthesiologists with a lead time of approximately 15 minutes to act — before, not after — hypotension occurs, by using a machine learning algorithm trained with approximately 1.5 million minutes of arterial pressure waveform data.

The clinical validation of the HPI algorithm in the HYPE randomized controlled trial (422 patients, multicenter, Europe) showed that the time-weighted average of intraoperative hypotension was reduced by about 59% compared to the standard monitoring management group, which is considered a clinically meaningful difference, since the duration of hypotension is correlated with postoperative acute kidney injury, myocardial injury, and 30-day mortality.

Automated closed-loop hemodynamic management is an emerging technology area with the closed-loop vasopressor management system (CVMP) developed by Vanderbilt University Medical Center showing in clinical trials that automated management led to more consistent achievement of blood pressure and cardiac output targets and a reduction in total vasopressor exposure when compared to manual physician management. Furthermore, the global AI-enabled hemodynamic monitoring software market will be valued at a little more than USD 145 million by 2024 and is expected to grow at a CAGR of 21.6% till 2035, primarily driven by the fact that the integration of machine learning capabilities into hemodynamic monitoring platforms is becoming a key competitive differentiator among major device manufacturers.

Category Wise Insights

By Product Type

Why Do Minimally Invasive Cardiac Output Monitoring Devices Lead the Market?

Thus, minimally invasive cardiac output monitoring devices, which represent a fundamental paradigm shift from the previous 20 years of pulmonary artery catheter-based (PAC) invasive hemodynamic monitoring, where a balloon-tipped flotation catheter was inserted into the central venous system, under fluoroscopic or pressure-waveform guidance, to the pulmonary artery to obtain cardiac output, have taken a dominant position in the market that accounts for about 44% of total market revenue by 2025.

The most important clinical moment for this paradigm change was the publication of the PACMAN trial in 2005 and the subsequent Cochrane meta-analysis of 13 randomized controlled trials (RCTs) in 2013 with a total of 5,051 patients showing no mortality benefit but significant procedure related complication rates with routine pulmonary artery catheter (PAC) use in mixed ICU populations, resulting in a significant decline in the use of PACS in North American and European critical care units from about 5.6 PAC insertions per 100 ICU admissions in 1993 to 1.9 PAC insertions per 100 ICU admissions in 2024.

By Technology

Why Does Thermodilution Lead the Cardiac Output Monitoring Technology Segment?

Thermodilution accounts for about 36% of the total revenue in the technology segment, and because it is the established clinical reference standard (CRS) against which all newer technologies of cardiac output monitoring are validated, thermodilution has a “science credibility” position that bolsters its role in high-acuity clinical environments where accuracy and reliability are key. The thermodilution principle, which is the injection of a cold saline bolus into the central vein or right atrium with a resultant change in temperature in the pulmonary artery (PAC thermodilution) — has been continuously validated as a cardiac output measurement method across five decades of clinical use in virtually every type of hemodynamic abnormality encountered in clinical practice.

Transpulmonary thermodilution — implemented through the PiCCO system requiring only central venous and arterial line access without the need for pulmonary artery catheterization—has become the preferred thermodilution method in contemporary clinical practice, combining the accuracy heritage of the thermodilution principle with the reduced procedural risk of minimally invasive vascular access, while additionally providing the volumetric hemodynamic parameters of GEDV and EVLW that are not measurable by PAC thermodilution.

By End Use

Why Do Hospitals and ICUs Lead the Cardiac Output Monitoring End Use Segment?

Hospitals and ICUs account for about 68% of total cardiac output monitoring device market revenue in 2025, which reflects the logic of use of cardiac output monitoring devices in fundamental clinical practice—where hemodynamic instability, multi-organ failure, and complex therapeutic management decisions provide the highest clinical value for continuous and accurate cardiac output data. One of the highest utilizing clinical environments for cardiac output monitoring is the cardiac surgical intensive care unit (ICU) — here, almost all of the cardiac surgery patients are monitored with cardiac output devices installed at the bedside, along with the central venous and arterial monitoring lines routinely used during surgery — creating a captive, high-monitoring-frequency, high-disposable-consumable-revenue model.

Hemodynamic monitoring-guided resuscitation with emphasis on maintaining cardiac output and central venous oxygen saturation as well as assessing fluid responsiveness is a major component of the implementation of the cardiac output monitoring bundle in the medical-surgical ICU, which is the second largest usage group for cardiac output monitoring across major economies at approximately 5.3 million cardiac monitoring admissions to the ICU annually in major economic countries combined, with the majority of these admissions being for septic shock.

Report Scope

Regional Analysis

How Big is the North America Cardiac Output Monitoring Device Market Size?

The cardiac output monitoring device market in North America is expected to witness a CAGR of 8.1% between 2026 and 2035, reaching approximately USD 1.02 billion in 2035.

Why Did North America Dominate the Market in 2025?

In 2025, North America will account for around 38% of global cardiac output monitoring device market revenue, a dominance that is based on the United States being the world's largest healthcare expenditure market, with total healthcare spending surpassing USD 4.5 trillion in 2024, representing around 17.3% of GDP, and the highest absolute number of cardiac surgical procedures, cardiac ICUs, and advanced hemodynamic monitoring device installations among all national markets.

Why is Europe the Second-Largest Market With Strong Clinical Evidence Infrastructure?

In 2025, the cardiac output monitoring device market in Europe is expected to generate approximately USD 347 million in revenue, with Germany, France, the United Kingdom and the Netherlands being the four largest national markets in Europe, accounting for approximately 65% of the total European cardiac output monitoring device market. The European scientific community has played a foundational role in building the clinical evidence base for cardiac output monitoring-guided hemodynamic therapy, with landmark multicenter trials such as OPTIMISE II and FEDORA, to name just two, in the field of septic shock management.

Why is Asia Pacific the Fastest-Growing Regional Market?

Asia Pacific is expected to generate roughly USD 199 million in cardiac output monitoring devices market revenue in 2025, accounting for around 16% of the global market revenue, and the region is likely to have the fastest growth—at a compound annual growth rate of 10.2%—between 2026 and 2035, thanks to the convergence of rapidly expanding critical care infrastructure, increasing cardiac surgery volume, an escalating prevalence of cardiovascular diseases due to dietary and lifestyle changes, and rising expenditure on healthcare by both government health systems and the private hospital sector in the region.

Why is LAMEA an Emerging Cardiac Output Monitoring Market With Infrastructure Investment Drivers?

LAMEA is expected to account for ~18% of the cardiac output monitoring device market revenue in 2025 and will experience a CAGR of 8.4% from 2026 to 2035, bolstered by the healthcare infrastructure investment plans in the Gulf Cooperation Council countries, the volume of cardiac surgeries in Latin America, the primary market in the region, and the steady improvement of critical care standards across emerging markets (EM) healthcare systems which is generating new demand for advanced hemodynamic monitoring capabilities in hospitals that were previously using basic vital sign monitoring.

Top Players in the Market and Their Offerings

• Edwards Lifesciences Corporation

• ICU Medical Inc. (LiDCO)

• Philips Healthcare

• GE HealthCare Technologies Inc.

• Getinge AB (PULSION Medical Systems / PiCCO)

• Mindray Medical International Limited

• Nihon Kohden Corporation

• Baxter International Inc. (Cheetah Medical / NICOM)

• Deltex Medical Group plc

• Tensys Medical Inc.

• Others

Key Developments

Leading manufacturers are innovating and commercializing new cardiac output monitoring devices as they invest in new cardiac monitoring platforms integrated with AI capabilities, new ambulatory monitoring devices, and new clinical indication clearances that are expanding the market for cardiac output monitoring technology.

• In April 2025: Edwards announced in April 2025 that it has invested USD 340 million into the development and positioning of its next-generation HemoSphere Ultra hemodynamic monitoring platform with the FDA clearance and commercial launch of the new HemoSphere Ultra sensor, which is the next generation of the FloTrac arterial pulse contour analysis sensor, along with the HemoSphere Ultra continuous cardiac output system for the pulmonary artery catheter, which is designed to be used with the company's ClearSight non-invasive cardiac output monitoring platform for the finger cuff and automated GDHT fluid responsiveness scoring and wireless data transmission to the hospital electronic health record system, representing the company's first fully integrated invasive to non-invasive cardiac output monitoring platform across all clinical settings from OR to ICU to heart failure clinic.

• In February 2025: PiCCO3, the third generation of the transpulmonary thermodilution and pulse contour analysis platform, is now commercially available with machine learning-based hemodynamic trend analysis, automated EVLW trajectory alerting for ARDS management, and integration with Getinge's Servo-U mechanical ventilator for automated lung-protective ventilation adjustment based on real-time EVLW data, representing the first commercially available integrated cardiopulmonary monitoring and management platform for ARDS patients in which fluid management optimization and lung-protective ventilation are the backbone of evidence-based management, applied to the ~3 million annual ARDS cases worldwide.

In this context, these strategic product developments are indicative of the ongoing convergence of cardiac output monitoring toward full integration of multiple monitoring modalities, predictive abilities using machine learning to detect deterioration, and increasingly, therapeutic devices to provide closed-loop hemodynamic management—a trajectory that is increasingly raising the clinical value proposition of cardiac output monitoring beyond passive data display to active clinical decision support and therapeutic guidance.

The Cardiac Output Monitoring Device Market is segmented as follows:

By Product Type

• Invasive Cardiac Output Monitoring Devices

  • Pulmonary Artery Catheter (PAC) Systems

  • Continuous Cardiac Output PAC Systems

  • Right Heart Catheterization Systems

• Minimally Invasive Cardiac Output Monitoring Devices

  • Arterial Pulse Contour Analysis Systems

  • Transpulmonary Thermodilution Systems

  • Esophageal Doppler Monitoring Systems

  • Lithium Dilution Cardiac Output Systems

• Non-Invasive Cardiac Output Monitoring Devices

  • Bioimpedance Cardiography (ICG) Systems

  • Bioreactance Monitoring Systems

  • Non-Invasive PPG-Based Cardiac Output Monitors

  • Transthoracic Echocardiography-Based Systems

  • Wearable & Ambulatory Hemodynamic Monitors

By Technology

• Thermodilution

  • Intermittent Bolus Thermodilution (PAC)

  • Continuous Thermodilution (Continuous CO PAC)

  • Transpulmonary Thermodilution (PiCCO, EV1000)

• Pulse Contour Analysis

  • Calibrated Pulse Contour Analysis (PiCCO, LiDCO Plus)

  • Uncalibrated Pulse Contour Analysis (FloTrac/Vigileo, LiDCO Rapid)

  • Volume Clamp / Vascular Unloading Technique (ClearSight)

• Fick Method

  • Direct Fick Method (Oxygen Consumption Measurement)

  • Indirect Fick Method (CO₂ Rebreathing)

• Echocardiography-Based Monitoring

  • Transthoracic Echocardiography (TTE) Cardiac Output

  • Transesophageal Echocardiography (TEE) Cardiac Output

  • Esophageal Doppler Monitoring (EDM)

  • Automated Stroke Volume Estimation (AI-Enhanced Echo)

• Bioimpedance & Bioreactance

  • Thoracic Electrical Bioimpedance (TEB)

  • Bioreactance (Phase Shift Analysis)

  • Whole-Body Bioimpedance Cardiography

• Other Technologies

  • Dye Dilution Method

  • Arterial Pressure Waveform Analysis (APWA)

  • Photoplethysmography (PPG)-Based CO Estimation

  • Ballistocardiography

By End Use

• Hospitals & ICUs

  • Cardiac Surgical Intensive Care Units (CSICUs)

  • Medical-Surgical ICUs & Mixed Critical Care Units

  • Cardiac Catheterization Laboratories

  • Emergency Departments & Resuscitation Bays

  • Operative & Post-Anesthesia Care Units (PACUs)

• Ambulatory Surgical Centers

  • High-Risk Ambulatory Surgical Procedures

  • Outpatient Cardiac Monitoring Programs

• Cardiac Care Centers

  • Heart Failure Clinics & Remote Monitoring Programs

  • Cardiac Rehabilitation Centers

  • Electrophysiology & Structural Heart Programs

• Other End Users

  • Military & Trauma Medical Facilities

  • Home Health & Telehealth Platforms

  • Academic & Clinical Research Institutions

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America